Literature DB >> 12144682

Analysis of clinicopathologic factors in malignant mixed Müllerian tumors of the uterine corpus.

P Inthasorn1, J Carter, S Valmadre, P Beale, P Russell, C Dalrymple.   

Abstract

The aim of this study was to retrospectively analyze the clinical and pathologic data of a series of patients presenting to our unit with uterine malignant mixed Müllerian tumors (MMMT) to attempt to identify prognostic factors and relate them to survival. Thirty-seven patients diagnosed with MMMT of the uterus from 1988 through 2000 were identified from the gynecological tumor registry. Data was abstracted and analyzed. The effect of a variety of clinical, histopathologic, and surgical variables on recurrence and survival were analyzed by univariate and multivariate analyses. Patients tended to be postmenopausal, overweight, hypertensive, and presented with abnormal bleeding. Preoperatively 28 (76%) were thought to have clinical stage I-II disease. Nine (32%) were upstaged based on surgical data. Five (56%) of these patients were found to have gross extrauterine disease and four (44%) were found subsequently to have microscopic extrauterine disease. Twenty (54%) patients underwent lymph node dissection and positive nodes were found in seven (35%) patients. Nine patients underwent omentectomy and disease was found in three (33%). Peritoneal washings were positive in three of 16 patients (19%). At the completion of primary surgery, 27 (75%) patients had no residual disease. Twelve (44%) of these patients had recurrence of disease. Median disease-free interval prior to first recurrence was 15 months. Median overall survival was 30 months. Log-rank analysis performed on multiple variables, including stage, age, residual disease, and depth of myometrial invasion showed a statistically significant association with overall survival probability. Only stage remained a significant independent variable predictive of overall survival (P = 0.034). We found that stage was an independent prognostic factor for overall survival in patients with uterine MMMT. Age, depth of myometrial invasion, and residual tumor were significant prognostic factors on univariate analysis. These factors may be a guide in order to select a group of high risk patients that may benefit from adjuvant therapy.

Entities:  

Mesh:

Year:  2002        PMID: 12144682     DOI: 10.1046/j.1525-1438.2002.01117.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  8 in total

1.  Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas.

Authors:  İrfan Cicin; Tahsin Özatlı; Esma Türkmen; Türkan Özturk; Melike Özçelik; Devrim Çabuk; Ayşe Gökdurnalı; Özlem Balvan; Yaşar Yıldız; Metin Şeker; Nuriye Özdemir; Burcu Yapar; Özgür Tanrıverdi; Yusuf Günaydin; Serkan Menekşe; Berna Öksüzoğlu; Asude Aksoy; Bülent Erdogan; M Bekir Hacıoglu; Erkan Arpaci; Alper Sevinç
Journal:  Balkan Med J       Date:  2016-09-01       Impact factor: 2.021

2.  A Study of Prognostic Factors of Chinese Patients with Gynecologic Tract Carcinosarcomas Prognosis of Gynecologic Carcinosarcomas.

Authors:  Dan Ye; Hao-Ran Shen; Liangqing Yao
Journal:  Cancer Manag Res       Date:  2020-10-29       Impact factor: 3.989

3.  18F-fluorodeoxyglucose positron emission tomography in uterine carcinosarcoma.

Authors:  Kung-Chu Ho; Chyong-Huey Lai; Tzu-I Wu; Koon-Kwan Ng; Tzu-Chen Yen; Gigin Lin; Ting-Chang Chang; Chun-Chieh Wang; Swei Hsueh; Huei-Jean Huang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-19       Impact factor: 9.236

4.  Evaluation of postoperative chemotherapy in patients with uterine carcinosarcoma: a retrospective survey of the Tohoku Gynecologic Cancer Unit.

Authors:  Ai Otsuki; Takeo Otsuki; Hideki Tokunaga; Hitoshi Niikura; Satoru Nagase; Takashi Sugiyama; Masafumi Toyoshima; Hiroki Utsunomiya; Yoshihito Yokoyama; Hideki Mizunuma; Naoki Sato; Yukihiro Terada; Tadahiro Shoji; Toru Sugiyama; Kenji Nakahara; Tsuyoshi Ohta; Hidekazu Yamada; Toru Tase; Hiroshi Nishiyama; Keiya Fujimori; Tadao Takano; Fumiaki Takahashi; Yoh Watanabe; Nobuo Yaegashi
Journal:  Int J Clin Oncol       Date:  2014-07-18       Impact factor: 3.402

5.  Uterine carcinosarcomas (malignant mixed müllerian tumours): a review with special emphasis on the controversies in management.

Authors:  Rani Kanthan; Jenna-Lynn Senger
Journal:  Obstet Gynecol Int       Date:  2011-10-05

6.  Adjuvant treatment modalities, prognostic predictors and outcomes of uterine carcinosarcomas.

Authors:  Kemal Gungorduk; Aykut Ozdemir; Ibrahim E Ertas; Mehmet Gokcu; Elcin Telli; Tufan Oge; Ahmet Sahbaz; Sevil Sayhan; Muzaffer Sanci; Mehmet Harma; Sinan Ozalp
Journal:  Cancer Res Treat       Date:  2014-09-04       Impact factor: 4.679

7.  Outcome and Predictive Factors in Uterine Carcinosarcoma Using Postoperative Radiotherapy: A Rare Cancer Network Study.

Authors:  Daniel R Zwahlen; Ulrike Schick; Yasemin Bolukbasi; Juliette Thariat; Roxolyana Abdah-Bortnyak; Abraham Kuten; Sefik Igdem; Hale Caglar; Zeynep Ozsaran; Kristina Loessl; Kaouthar Khanfir Belkaaloul; Sylviane Villette; Hansjörg Vees
Journal:  Rare Tumors       Date:  2016-06-29

8.  Uterine Carcinosarcoma with Alpha-Fetoprotein-Producing Hepatoid Component: A Case Report and Literature Review.

Authors:  Joshua J X Li; Jacqueline H S Lee; Vicky T C Chan; Mei-Yung Yu
Journal:  Case Rep Pathol       Date:  2018-06-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.